,
Making cancer care smart with Oncotype IQ genomic tests
Improve outcomes by optimizing cancer care treatment and monitoring
LEARN MORE

LUGPA 2021 Annual Meeting

November 11-13, 2021 - Chicago, IL

Visit us at LUGPA 2021 to learn more about how the Oncotype test portfolio helps guide treatment decisions for your localized to advanced prostate cancer patients.

Oncotype MAP Pan-Cancer Tissue Test Webinar

What Can We Learn from NSCLC?

Learn how NGS-based comprehensive genomic profiling has enhanced patient care through real-world NSCLC case studies, presented by Drs. Edgardo Santos, Snehal Thakkar, and Jean-Paul De La O.

UroCareLive Webinar

Available Now On-Demand

Drs. Sellinger and Shore discuss “Incorporating Genomic Profiling and Biomarker Testing in Clinical Practice” using the Oncotype tests for advanced prostate cancer patients.

New Cut Point for Unfavorable Intermediate and High-Risk Patients

Oncotype DX Genomic Prostate Score

The Oncotype DX GPS assay stratifies unfavorable intermediate and high-risk patients into two distinct groups with highly differing long-term outcomes.

Medicare Coverage Update

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score Assay is now covered by Medicare for all intermediate-risk prostate cancer patients.
Improving Patient Outcomes

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.™